Lead Sponsor

Sandoz

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Male or female adults (age \> / = 18 years)
•Diagnosed with one of the following types and stages of tumors: stage III or IV breast cancer; stage III or IV ovarian cancer; stage III or IV bladder cancer; stage III or IV lung cancer; metastatic prostate cancer; stage III or IV diffuse large B-cell lymphoma; multiple myeloma.
•Planned to receive primary prophylaxis with filgrastim biosimilar (EP2006) at the first cycle of chemotherapy (regardless of line of chemotherapy); or receiving secondary prophylaxis with filgrastim biosimilar (EP2006) irrespective of chemotherapy cycle.
•Treated with commercially available filgrastim biosimilar per physician's best clinical judgment and per current European filgrastim biosimilar (EP2006) label.
•Female patients must be either post-menopausal for one year or surgically sterile or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Oral contraceptive use is allowed.
•Informed written consent to participate in the study by patients or their legal guardian.

•Patients with myeloid malignancies, with the exception of multiple myeloma.
•Sensitivity to filgrastim biosimilar or any other CSF.
•Hypersensitivity to E. coli-derived proteins.
•Radiotherapy to ≥ 20% of total body bone.
•Infection within two weeks of starting current line of chemotherapy.
•Patients with several medical condition(s) that in view of the investigator prohibits participation in the study.
•Patients with willfully negligent nonadherence to their cancer treatment.
•Use of any investigational agent in the 30 days prior to enrollment.
•Women of childbearing potential not using the contraception method(s) described above.
•Women who are breastfeeding.

Related studies

NCT06312137 · Non Small Cell Lung Cancer

NCT07586215 · Breast Cancer Metastatic

NCT07042802 · Ovarian Cancer

NCT06980038 · Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, and more

NCT07580196 · Prostate Cancer

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor